Ling Eleanor M, Smith Trevor, Nguyen X Dao, Pridgeon Carol, Dallman Margaret, Arbery Justine, Carr Victoria A, Robinson Douglas S
Department of Allergy, National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.
Lancet. 2004 Feb 21;363(9409):608-15. doi: 10.1016/S0140-6736(04)15592-X.
Allergic diseases are frequent and rising in prevalence, and result from activation of T-helper (Th) 2 cells by allergens. CD4+CD25+ regulatory T cells suppress T-cell activation in vitro and prevent pathological findings in animal models of disease. We aimed to investigate whether the amount of inhibition of allergic responses by CD4+CD25+ T cells was related to atopy and allergic disease.
Blood CD4+CD25+ and CD4+CD25- T cells were isolated from three groups of donors: non-atopic individuals; those atopic with no present symptoms; and patients with hayfever studied during and out of the grass-pollen season. We investigated the ability of CD25+ T cells from these donors to suppress allergen-stimulated T-cell proliferation and cytokine production in vitro.
CD4+CD25+ T cells from non-atopic donors suppressed proliferation and interleukin 5 production by their own allergen-stimulated CD4+CD25- T cells. Inhibition of proliferation by CD4+CD25+ T cells from atopic donors was significantly reduced (p=0.0012), and was even more diminished by CD4+CD25+ T cells isolated from patients with hayfever during the pollen season (p=0.0003). In patients with hayfever, out-of-season suppression remained less than that seen by regulatory cells from non-atopic donors.
Allergic disease can result from an inappropriate balance between allergen activation of regulatory CD4+CD25+ T cells and effector Th2 cells. This imbalance could result from a deficiency in suppression by regulatory T cells or strong activation signals could overcome such regulation. Treatment to enhance regulatory T-cell responses, in concert with reduction of Th2 cell activation, might be useful in prevention and treatment of allergic disease.
过敏性疾病很常见且患病率不断上升,是由变应原激活辅助性T(Th)2细胞所致。CD4+CD25+调节性T细胞在体外可抑制T细胞激活,并能预防疾病动物模型中的病理表现。我们旨在研究CD4+CD25+ T细胞对过敏反应的抑制量是否与特应性和过敏性疾病相关。
从三组供体中分离出血液中的CD4+CD25+和CD4+CD25- T细胞:非特应性个体;有特应性但无当前症状者;以及在草花粉季节期间和非草花粉季节研究的花粉症患者。我们研究了这些供体的CD25+ T细胞在体外抑制变应原刺激的T细胞增殖和细胞因子产生的能力。
非特应性供体的CD4+CD25+ T细胞抑制了其自身变应原刺激的CD4+CD25- T细胞的增殖和白细胞介素5的产生。特应性供体的CD4+CD25+ T细胞对增殖的抑制作用显著降低(p=0.0012),而从花粉季节的花粉症患者中分离的CD4+CD25+ T细胞对增殖的抑制作用则更弱(p=0.0003)。在花粉症患者中,非花粉季节的抑制作用仍低于非特应性供体的调节性细胞所观察到的抑制作用。
过敏性疾病可能源于调节性CD4+CD25+ T细胞和效应性Th2细胞的变应原激活之间的不适当平衡。这种失衡可能是由于调节性T细胞抑制不足,或者强烈的激活信号可能克服这种调节。增强调节性T细胞反应的治疗,与减少Th2细胞激活协同作用,可能对过敏性疾病的预防和治疗有用。